|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,925.50 GBX | +0.13% |
|
-2.95% | +5.54% |
| 06-19 | FTSE 100 flat as investors weigh US-Iran peace talks, energy stocks support | RE |
| 06-18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| Market Cap | 76.72B 101B 88.49B 81.96B 144B 9,577B 145B 972B 377B 4,714B 381B 373B 16,368B | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 90.98B 120B 105B 97.18B 171B 11,356B 172B 1,153B 447B 5,590B 452B 442B 19,408B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GSK plc
| 1 day | +0.13% | ||
| 1 week | -2.95% | ||
| Current month | +2.34% | ||
| 1 month | +1.24% | ||
| 3 months | -1.56% | ||
| 6 months | +5.68% | ||
| Current year | +5.54% |
| 1 week | 1,906 |  | 1,989.5 |
| 1 month | 1,805 | | 2,191 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-07 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 05-21 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 05-14 | Buy | Executive/Senior Manager | 82 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | -2.95% | +34.18% | +42.44% | 101B | |
| -1.21% | -3.04% | +39.94% | +145.38% | 980B | |
| -2.48% | -5.18% | +51.52% | +39.07% | 550B | |
| -2.14% | -4.94% | +16.71% | +56.15% | 382B | |
| +0.25% | -3.09% | +23.00% | +15.81% | 316B | |
| +0.61% | -1.69% | +25.42% | +13.64% | 272B | |
| +0.22% | -3.10% | +24.25% | +30.21% | 268B | |
| +4.59% | +1.98% | -40.02% | -45.89% | 199B | |
| -1.19% | -4.95% | +16.56% | +47.00% | 182B | |
| -1.35% | -1.46% | +14.59% | +56.94% | 154B | |
| Average | -0.26% | -3.01% | +20.62% | +40.07% | 340.38B | |
| Weighted average by Cap. | -0.75% | -3.65% | +27.99% | +63.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.79B 44.7B 38.98B 36.1B 63.38B 4,218B 63.76B 428B 166B 2,076B 168B 164B 7,209B | 35.48B 46.93B 40.92B 37.9B 66.53B 4,428B 66.94B 450B 174B 2,180B 176B 172B 7,568B |
| Net income | 6.27B 8.29B 7.23B 6.69B 11.75B 782B 11.82B 79.41B 30.78B 385B 31.12B 30.45B 1,337B | 6.67B 8.82B 7.69B 7.12B 12.51B 832B 12.58B 84.52B 32.75B 410B 33.12B 32.41B 1,423B |
| Net Debt | 14.25B 18.85B 16.44B 15.22B 26.73B 1,779B 26.89B 181B 70B 876B 70.77B 69.25B 3,040B | 11.19B 14.8B 12.91B 11.95B 20.98B 1,397B 21.11B 142B 54.95B 687B 55.56B 54.37B 2,387B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/26 | 1,925.50 p | +0.13% | 15,121,490 |
| 18/06/26 | 1,923.00 p | -2.51% | 7,565,889 |
| 17/06/26 | 1,972.50 p | +1.15% | 4,713,671 |
| 16/06/26 | 1,950.00 p | -0.41% | 6,759,886 |
| 15/06/26 | 1,958.00 p | -1.31% | 7,053,702 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
